Investigational drug · Phase 2
INO-9012
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC, Glioblastoma, Urothelial Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
16
Any phase or sponsor naming "INO-9012"
First trial start
2018
May 31, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INO-9012", any sponsor or status.
- Phase 113
Conditions studied
As listed on its trial records.
- HCC
- Glioblastoma
- Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INO-9012" as an intervention, largest first.
- Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersPivotal-lookingCompleted
Inovio PharmaceuticalsIndustry
NCT02464670 · 240 participants · Start May 2015 · Primary completion May 24, 2018
Drug: INO-4201; INO-4202 and 4 more · For: Ebola Vaccine
Sites: Miami, Florida; Kansas City, Missouri; Philadelphia, Pennsylvania
Inovio PharmaceuticalsIndustry
NCT02960594 · 93 participants · Start Dec 2014 · Primary completion Nov 9, 2018
Drug: INO-1400; INO-9012 and 1 more · For: Breast Cancer; Lung Cancer; Pancreatic Cancer and 6 more
Sites: Detroit, Michigan; Rochester, Minnesota; Chapel Hill, North Carolina · 6 sites in all
Geneos TherapeuticsIndustry
NCT07722741 · 90 participants (planned) · Start Sep 2026 · Primary completion Sep 2029
Drug: GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation; INO-9012 · For: HCC
Sites: Atlanta, Georgia; New Orleans, Louisiana; Baltimore, Maryland · 9 sites in all
Inovio PharmaceuticalsIndustry
NCT02514213 · 62 participants · Start Jul 2015 · Primary completion Dec 12, 2017
Drug: 2mg INO-5150 and electroporation device CELLECTRA®-5P; 8.5mg INO-5150 and electroporation device CELLECTRA®-5P and 2 more · For: Prostate Cancer
Sites: Baltimore, Maryland; Detroit, Michigan; Omaha, Nebraska · 10 sites in all
Steven DeeksAcademic, hospital or other
NCT03606213 · 56 participants · Start Aug 1, 2018 · Primary completion May 17, 2021
Drug: PENNVAX-GP; INO-6145 and 1 more · For: HIV-1-infection
Sites: Los Angeles, California; San Francisco, California
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Active, not recruiting
Inovio PharmaceuticalsIndustry
NCT03491683 · 52 participants · Start May 31, 2018 · Primary completion Dec 31, 2027
Drug: INO-5401; INO-9012 and 2 more · For: Glioblastoma
Sites: Duarte, California; Palo Alto, California; San Francisco, California · 21 sites in all
- INO 5401 Vaccination in BRCA1/2 Mutation CarriersActive, not recruiting
University of PennsylvaniaAcademic, hospital or other
NCT04367675 · 44 participants (planned) · Start Apr 20, 2021 · Primary completion Dec 2026
Drug: INO-5401; INO-9012 · For: BRCA1/2 Mutation
Sites: Philadelphia, Pennsylvania
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03439085 · 41 participants · Start Nov 14, 2018 · Primary completion Sep 20, 2022
Drug: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457; Durvalumab · For: Human Papillomavirus-16 Positive; Human Papillomavirus-18 Positive; Metastatic Malignant Neoplasm and 18 more
Sites: Houston, Texas
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCActive, not recruiting
Geneos TherapeuticsIndustry
NCT04251117 · 36 participants · Start Mar 1, 2020 · Primary completion Nov 29, 2024
Drug: GNOS-PV02; INO-9012 and 1 more · For: HCC
Sites: Baltimore, Maryland; New York, New York; Auckland, New Zealand
Inovio PharmaceuticalsIndustry
NCT03502785 · 35 participants · Start Jul 24, 2018 · Primary completion May 9, 2025
Drug: INO-5401; INO-9012 and 1 more · For: Urothelial Carcinoma
Sites: Phoenix, Arizona; Tampa, Florida; Baltimore, Maryland · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection.
Jacobson JM, Zahrieh D, Strand CA, et al. · Cancer Prev Res (Phila) 2023
- Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
Vonderheide RH, Kraynyak KA, Shields AF, et al. · J Immunother Cancer 2021
- CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Shore ND, Morrow MP, McMullan T, et al. · Mol Ther 2020
- Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis.
Aggarwal C, Cohen RB, Morrow MP, et al. · Vaccines (Basel) 2020
Also in development for HCC
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- tirapazaminePhase 32 trials
Zhejiang Raygene Pharmaceuticals Co., Ltd · HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic
- GNOS-PV02Phase 22 trials
Geneos Therapeutics · HCC
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- PM1009Phase 21 trial
Biotheus Inc. · HCC, Liver Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.